Published on in Vol 5, No 4 (2016): Oct-Dec

A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)

A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)

A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)

Journals

  1. Kuwahara M, Kusunoki S. Mechanism and spectrum of anti-glycolipid antibody-mediated chronic inflammatory demyelinating polyneuropathy. Clinical and Experimental Neuroimmunology 2018;9(1):65 View
  2. Misawa S, Suichi T. Guillain‐Barré syndrome: Novel treatment by complement inhibition. Clinical and Experimental Neuroimmunology 2020;11(2):90 View
  3. Uncini A, Vallat J. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. Journal of Neurology, Neurosurgery & Psychiatry 2018;89(6):627 View
  4. Liu S, Dong C, Ubogu E. Immunotherapy of Guillain-Barré syndrome. Human Vaccines & Immunotherapeutics 2018:1 View
  5. Keller C, Quast I, Dalakas M, Lünemann J. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. Journal of Neuroimmunology 2019;330:23 View
  6. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Nagashima T, Shimizu T, Hirotani M, Kadoya M, Nakahara J, Shimizu J, Tanaka M, Sobue G, Katsuno M, Yamaguchi H, Ogata H. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519 View
  7. Doets A, Hughes R, Brassington R, Hadden R, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2020 View
  8. Pilch K, Spaeth P, Yuki N, Wakerley B. Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Review of Neurotherapeutics 2017;17(6):579 View
  9. Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Ikeda S, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. Journal of the Peripheral Nervous System 2017;22(4):433 View
  10. Wijdicks E, Klein C. Guillain-Barré Syndrome. Mayo Clinic Proceedings 2017;92(3):467 View
  11. Misawa S. Development of new treatments with drug repositioning strategies: POEMS and Guillain‐Barré syndrome. Neurology and Clinical Neuroscience 2021;9(1):50 View